SAN DIEGO--(BUSINESS WIRE)--VedaBio, the biotechnology company leading a paradigm-shift in molecular detection, today announced that Frédéric Sweeney, PhD, has been appointed President and Chief Executive Officer. He previously held the role of Executive Chairman, President and Chief Operating Officer at VedaBio. The company also announced the appointment of industry veteran Maurice Exner, PhD, as Chief Operating Officer.
“It is a privilege to serve a team that is truly operating at the forefront of scientific innovation, as we work together to create a fundamental new model in the field of molecular detection,” said Fred Sweeney, PhD, President and Chief Executive Officer, VedaBio. “The addition of Maurice is a significant milestone as we embark on this next phase of our growth. His deep experience and long track record of success will undoubtably add significant value and I look forward to working alongside him and the rest of our team as we continue the development of our CRISPR Cascade platform.”
VedaBio emerged from stealth in October 2023 with initial funding of over $40 Million backed by lead investor OMX Ventures.
“I am continuously impressed by the executive and scientific talent of the VedaBio team. Naming Fred CEO and appointing Maurice as COO is a clear testament to the company entering our next phase of growth. The VedaBio team shares a deep commitment to the mission of revolutionizing molecular detection and to empowering major advances across multiple applications,” said Craig Asher, Lead Director of VedaBio and Managing Director, OMX Ventures.
Frédéric Sweeney, PhD, Board Director, President and Chief Executive Officer, brings extensive experience in start-up and high growth healthcare company environments with a focus on venture capital, corporate development and operations. Prior to joining VedaBio, Fred held numerous executive roles at MeMed Diagnostics, bioMérieux, Versant Ventures, Northern Biologics, and T2 Biosystems.
Maurice Exner, PhD, brings more than two decades of experience in global research and development leadership and strategy to VedaBio. Prior to joining the team, Maurice served as Chief Scientific Officer at Sherlock Biosciences, and earlier as Vice President of Global R&D at Thermo Fisher Scientific's Genetic Sciences organization. He has also served as Vice President of R&D, Assay Development and Clinical Affairs at Hologic, in addition to Product Development/M&A Integration at Abbott Point of Care and R&D Manager at Quest Diagnostics. Maurice received his BSc in Microbiology from the University of Regina, and his PhD in Microbiology from the University of British Columbia.
About CRISPR Cascade™
VedaBio’s CRISPR Cascade is a disruptive new molecular detection platform that operates with a combination of unprecedented speed and accuracy. The CRISPR Cascade platform eliminates the need for target amplification while maintaining PCR-level accuracy, all with an ultra-rapid analytical turnaround time. Unlike PCR or other DNA/RNA amplification technologies where assay design complexity significantly increases with multiplexing, the CRISPR Cascade removes several fundamental constraints, enabling incredibly simple, highly multiplexed assays without signal loss or cross reactivity issues, for example. With performance that combines highly sensitive, accurate and ultra-rapid results, the CRISPR Cascade unlocks a universe of possibilities.
About VedaBio
VedaBio is revolutionizing molecular biology with its breakthrough platform for ultra-rapid molecular detection of multiplexed analytes, delivering best-in-class accuracy without the need for target amplification. Our CRISPR Cascade™ platform is poised to emerge as a new gold standard tool to empower decision-making across multiple industries. Learn more at vedabio.com.
